Screener
Aurinia Pharmaceuticals AUPH Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Aurinia Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The source filing: Aurinia Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 8:16 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001600620-26-000062
FAQ
- What is Aurinia Pharmaceuticals's return on equity?
- Aurinia Pharmaceuticals (AUPH) reported return on equity of 66.1% in Q2 2026.
- How has Aurinia Pharmaceuticals's return on equity changed year-over-year?
- Aurinia Pharmaceuticals's return on equity increased by 281.6% year-over-year, from 17.3% to 66.1%.
- What is the long-term trend for Aurinia Pharmaceuticals's return on equity?
- Over 5 years (2020 to 2025), Aurinia Pharmaceuticals's return on equity has grown at a 15.6% compound annual growth rate (CAGR), from -29.1% to 59.9%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.
Ask your AI about Aurinia Pharmaceuticals's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude